Dasatinib inhibits the growth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFRα

Experimental Hematology

Volumn 36, Issue 10, 2008, Pages 1244-1253

  Baumgartner, Christian ^a   Gleixner, Karoline V ^a   Peter, Barbara ^a,b   Ferenc, Veronika ^a   Gruze, Alexander ^c   Remsing Rix, Lily L ^d   Bennett, Keiryn L ^d   Samorapoompichit, Puchit ^e   Lee, Francis Y ^f   Pickl, Winfried F ^c   Esterbauer, Harald ^a   Sillaber, Christian ^a   Superti Furga, Giulio ^d   Valent, Peter ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^e Medical University of Vienna Institute of Histology and Embryology   (Austria)

^f BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; IMATINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG EFFECT; EOSINOPHILIC LEUKEMIA; FLOW CYTOMETRY; HUMAN; HUMAN CELL; NICK END LABELING; PRIORITY JOURNAL;

APOPTOSIS; CELL DIVISION; CELL LINE, TUMOR; CELL SURVIVAL; DNA REPLICATION; EOSINOPHILS; FLOW CYTOMETRY; HUMANS; HYPEREOSINOPHILIC SYNDROME; MRNA CLEAVAGE AND POLYADENYLATION FACTORS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SEQUENCE DELETION; THIAZOLES; THYMIDINE;

EID: 52049122130     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2008.04.017     Document Type: Article

References (49)

1. Fauci A.S., Harley J.B., Roberts W.C., Ferrans V.J., Gralnick H.R., and Bjornson B.H. NIH conference. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations. Ann Intern Med 97 (1982) 78-92
2. Bain B.J. Eosinophilic leukaemias and the idiopathic hypereosinophilic syndrome. Br J Haematol 95 (1996) 2-9
3. Oliver J.W., Deol I., Morgan D.L., and Tonk V.S. Chronic eosinophilic leukemia and hypereosinophilic syndromes. Proposal for classification, literature review, and report of a case with a unique chromosomal abnormality. Cancer Genet Cytogenet 107 (1998) 111-117
4. Bain B., Pierre R., Imbert M., Vardiman J.W., Brunning R.D., and Flandrin G. In: Jaffe E.S., Harris N.L., Stein H., and Vardiman J.W. (Eds). World Health Organization (WHO) Classification of Tumours. Pathology & Genetics. Tumours of Haematopoietic and Lymphoid Tissues. Chronic eosinophilic leukemia and hypereosinophilic syndrome Vol. 1 (2001), WHO, Geneva 29-31
5. Gotlib J., Cools J., Malone III J.M., Schrier S.L., Gilliland D.G., and Coutré S.E. The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood 103 (2004) 2879-2891
6. Gotlib J. Molecular classification and pathogenesis of eosinophilic disorders: 2005 update. Acta Haematol 114 (2005) 7-25
7. Tefferi A. Modern diagnosis and treatment of primary eosinophilia. Acta Haematol 114 (2005) 52-60
8. Cools J., Stover E.H., and Gilliland D.G. Detection of the FIP1L1-PDGFRA fusion in idiopathic hypereosinophilic syndrome and chronic eosinophilic leukemia. Methods Mol Med 125 (2006) 177-187
9. Tefferi A., Patnaik M.M., and Pardanani A. Eosinophilia: secondary, clonal and idiopathic. Br J Haematol 133 (2006) 468-492
10. Stover E.H., Chen J., and Folens C. Activation of FIP1L1-PDGFRalpha requires disruption of the juxtamembrane domain of PDGFRalpha and is FIP1L1-independent. Proc Natl Acad Sci U S A 103 (2006) 8078-8083
11. Pardanani A., Ketterling R.P., Brockman S.R., et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 102 (2003) 3093-3096
12. Cools J., DeAngelo D.J., and Gotlib J. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348 (2003) 1201-1214
13. Coutré S., and Gotlib J. Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate. Semin Cancer Biol 14 (2004) 307-315
14. Pardanani A., Reeder T., Porrata L.F., et al. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood 101 (2003) 3391-3397
15. Pardanani A., and Tefferi A. Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders. Leuk Res 28 (2004) 47-52
16. Cortes J., Ault P., Koller C., et al. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood 101 (2003) 4714-4716
17. Baccarani M., Cilloni D., and Rondoni M. The efficacy of imatinib mesylate in patients with FIP1l1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica 92 (2007) 1173-1179
18. Jovanovic J.V., Score J., Waghorn K., et al. Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood 109 (2007) 4635-4640
19. Müller A.M., Martens U.M., Hofmann S.C., Bruckner-Tuderman L., Mertelsmann R., and Lubbert M. Imatinib mesylate as a novel treatment option for hypereosinophilic syndrome: two case reports and a comprehensive review of the literature. Ann Hematol 85 (2006) 1-16
20. Martinelli G., Malagola M., Ottaviani E., Rosti G., Trabacchi E., and Baccarani M. Imatinib mesylate can induce complete molecular remission in FIP1L1-PDGFR-a positive idiopathic hypereosinophilic syndrome. Haematologica 89 (2004) 236-237
21. Curtis C.E., Grand F.H., Musto P., et al. Two novel imatinib-responsive PDGFRA fusion genes in chronic eosinophilic leukaemia. Br J Haematol 138 (2007) 77-81
22. Lierman E., Folens C., Stover E.H., et al. Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant. Blood 108 (2006) 1374-1376
23. Cools J., Maertens C., and Marynen P. Resistance to tyrosine kinase inhibitors: calling on extra forces. Drug Resist Update 8 (2005) 119-129
24. von Bubnoff N., Gorantla S.P., Thone S., Peschel C., and Duyster J. The FIP1L1 PDGFRA T674I mutation can be inhibited by the tyrosine kinase inhibitor AMN107 (nilotinib). Blood 107 (2006) 4970-4971
25. Verstovsek S., Giles F.J., Quintas-Cardama A., et al. Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells. Leuk Res 30 (2006) 1499-1505
26. Cools J., Quentmeier H., Huntly B.J., et al. The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA positive chronic eosinophilic leukemia. Blood 103 (2004) 2802-2805
27. Cools J., Stover E.H., Wlodarska I., Marynen P., and Gilliland D.G. The FIP1L1 PDGFRalpha kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia. Curr Opin Hematol 11 (2004) 51-57
28. Talpaz M., Shah N.P., Kantarjian H., et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 354 (2006) 2531-2541
29. Shah N.P., Tran C., Lee F.Y., Chen P., Norris D., and Sawyers C.L. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305 (2004) 399-401
30. Shah N.P., Lee F.Y., Luo R., Jiang Y., Donker M., and Akin C. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood 108 (2006) 286-291
31. Hantschel O., Rix U., Schmidt U., et al. The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci U S A 104 (2007) 13283-13288
32. Tokarski J.S., Newitt J.A., Chang C.Y., et al. The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res 66 (2006) 5790-5797
33. Hochhaus A., Kantarjian H.M., Baccarani M., et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 109 (2007) 2303-2309
34. Van Cruchten S., and Van Den Broeck W. Morphological and biochemical aspects of apoptosis, oncosis and necrosis. Anat Histol Embryol 31 (2002) 214-223
35. Gorczyca W., Gong J., and Darzynkiewicz Z. Detection of DNA strand breaks in individual apoptotic cells by the in situ terminal deoxynucleotidyl transferase and nick translation assays. Cancer Res 53 (1993) 1945-1951
36. Detection of strand breaks in individual apoptotic cells by the in situ terminal deoxynucleotidal transferase and nick translation assays. Cancer Res 53 (1993) 1945-1951
37. Sillaber C., Gesbert F., Frank D.A., Sattler M., and Griffin J.D. STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells. Blood 5 (2000) 2118-2125
38. Gleixner K.V., Mayerhofer M., Aichberger K.J., et al. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood 107 (2006) 752-759
39. Rix U., Hantschel O., Dürnberger G., et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib reveal novel kinase and non-kinase targets. Blood 110 (2007) 4055-4063
40. Bradeen H.A., Eide C.A., O'Hare T., et al. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood 108 (2006) 2332-2338
41. Weisberg E., Catley L., Wright R.D., et al. Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias. Blood 109 (2007) 2112-2120
42. Kerkela R., Grazette L., Yacobi R., et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 12 (2006) 908-916
43. Rosti G., Martinelli G., and Baccarani M. In reply to "Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 13 (2007) 15
44. Atallah E., Durand J.B., Kantarjian H., and Cortes J. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood 110 (2007) 1233-1237
45. Plumas J., Gruart V., Aldebert D., et al. Human eosinophils from hypereosinophilic patients spontaneously express the p55 but not the p75 interleukin 2 receptor subunit. Eur J Immunol 21 (1991) 1265-1270
46. Enokihara H., Koike T., Nakamura Y., Saito K., and Furusawa S. Identification of surface molecules on eosinophils and lymphocytes in blood from patients with eosinophilia. Int Arch Allergy Immunol 114 Suppl 1 (1997) 72-74
47. Kneidinger M., Schmidt U., Rix U., et al. The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils. Blood 111 (2008) 3097-3107
48. Gleixner K.V., Rebuzzi L., Mayerhofer M., et al. Synergistic antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells. Exp Hematol 35 (2007) 1510-1521
49. Gleixner K.V., Mayerhofer M., Sonneck K., et al. Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT. Haematologica 92 (2007) 1451-1449